アプレア・セラピューティクスに関するコメント

$アプレア・セラピューティクス(APRE.US)$
NEWS
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
Aprea Therapeutics, Inc. announces positive pre-clinical findings for APR-1051, a WEE1 kinase inhibitor, indicating potential as a treatment for Cyclin E-overexpressing cancers. The company also received IND clearance for APR-1051 and presented details on the planned Phase 1 trial. ATRN-119, a n...

$アプレア・セラピューティクス(APRE.US)$ Karolinska Development's Portfolio Company Aprea Therapeutics Receives FDA IND Approval and Secures Funding of USD 34 Million
GlobeNewswire· 4 mins ago

$アプレア・セラピューティクス(APRE.US)$ buy now

$アプレア・セラピューティクス(APRE.US)$ Watching closely for IND For ATRN-1051, it  is expected to be submitted this quarter

$アプレア・セラピューティクス(APRE.US)$ Positive Outlook for Aprea Therapeutics: Promising Developments and Safety Profile of ATRN-119 Bolster Buy Rating

$アプレア・セラピューティクス(APRE.US)$ Item 8.01Other Events.
On October 16, 2023, Aprea Therapeutics, Inc. issued a press release announcing initial clinical data on ATRi, ATRN-119, and pre-clinical data on WEE1i, ATRN-1051, presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, supporting highly differentiated synthetic lethality portfolio.  A copy of the press release is filed as Exhibit 99.1 hereto and incorporated herein by reference.

$アプレア・セラピューティクス(APRE.US)$ Aprea Announces Preclinical Data Supporting Highly Differentiated WEE1 Inhibitor, ATRN-1051, Relative To Other WEE1 Inhibitors

Hello everyone,
We're seeking community insights on the potential movement of this stock in the coming one to two months. Do you anticipate it to rise or fall?
If you have any solid ideas, insider information, or news that might influence this stock's direction, kindly share in the comments section below. Your input is greatly valued!
Thank you for your participation.
$アプレア・セラピューティクス(APRE.US)$